Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Investing Activities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Cash from Investing Activities for 11 consecutive years, with -$492000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 38.98% to -$492000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.5 million, a 37.61% increase, with the full-year FY2025 number at -$5.5 million, up 37.61% from a year prior.
  • Cash from Investing Activities was -$492000.0 for Q4 2025 at Cartesian Therapeutics, up from -$1.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $28.1 million in Q1 2023 to a low of -$29.9 million in Q3 2022.
  • A 5-year average of -$617315.8 and a median of -$602000.0 in 2024 define the central range for Cash from Investing Activities.
  • Biggest YoY gain for Cash from Investing Activities was 5956.63% in 2021; the steepest drop was 16525.93% in 2021.
  • Cartesian Therapeutics' Cash from Investing Activities stood at $9.7 million in 2021, then plummeted by 43.54% to $5.5 million in 2022, then increased by 18.36% to $6.5 million in 2023, then tumbled by 105.45% to -$354000.0 in 2024, then tumbled by 38.98% to -$492000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Cash from Investing Activities are -$492000.0 (Q4 2025), -$1.3 million (Q3 2025), and -$2.6 million (Q2 2025).